CagriReta weight loss results — what to realistically expect.

CagriReta weight loss results are among the most striking ever recorded for a non-surgical obesity treatment — but understanding what to realistically expect requires looking past the headline percentages to the actual distribution of outcomes. CagriReta combines cagrilintide (an amylin analogue) with semaglutide (the GLP-1 in Ozempic and Wegovy) — the same combination studied as CagriSema in the landmark REDEFINE clinical trial programme. The REDEFINE-1 Phase 3 trial, published in the New England Journal of Medicine, found that 60% of participants achieved 20% or more weight loss, and 23% achieved 30% or more. This guide covers exactly what those numbers mean for you, the realistic timeline, and the factors that determine where in that range you are likely to land.

All clinical data referenced in this guide comes from the published REDEFINE-1 and REDEFINE-2 trial results and presentations at the American Diabetes Association 85th Scientific Sessions, alongside the NHS obesity treatment guidance.

REDEFINE-1 results — the headline numbers

REDEFINE-1 randomised 3,417 adults with overweight or obesity (without diabetes) to receive once-weekly CagriSema, semaglutide 2.4mg alone, cagrilintide 2.4mg alone, or placebo over 68 weeks, alongside standardised lifestyle interventions. The CagriReta weight loss results from this trial were described by investigators as among the most significant seen with any anti-obesity medication to date.

The “trial-product estimand” analysis reflects results among patients who adhered to treatment as prescribed — this is the most relevant figure for understanding what to expect if you follow the full CagriReta weight loss protocol consistently.

What realistic CagriReta weight loss results look like

The 60% and 23% figures above are population-level results — meaning real outcomes are distributed across a range rather than every patient achieving the same number. Understanding this distribution helps set realistic personal expectations for CagriReta weight loss results:

• Top responders (roughly 1 in 4 patients): 30% or more total body weight loss — comparable to bariatric surgery outcomes
• Strong responders (roughly 6 in 10 patients): 20% or more total body weight loss — substantial, life-changing results
• Moderate responders: 10 to 20% weight loss — still clinically meaningful and well above what most lifestyle-only interventions achieve
• Lower responders: a smaller proportion of patients achieve under 10% — often linked to inconsistent adherence, inadequate protein intake, or underlying metabolic factors

The most important takeaway: even patients at the lower end of the CagriReta weight loss results distribution are typically achieving more than most other interventions can deliver. The average across the full trial population — 22.7% — already exceeds what semaglutide alone achieves at its maximum dose.

CagriReta weight loss timeline

• Weeks 1–2: appetite reduction begins. Minimal weight loss — this is the tolerance and dose-finding phase
• Weeks 3–8: first meaningful weight loss appears as the dose escalates toward the target level
• Weeks 9–24: the most rapid phase of weight loss for most patients, as both the GLP-1 and amylin mechanisms reach full effect
• Weeks 25–52: continued steady weight loss at a slower but consistent rate
• Weeks 53–68+: approaching the trial endpoint results — many patients still losing weight at this stage rather than having plateaued

Unlike some weight loss interventions that plateau early, REDEFINE-1 data showed CagriReta weight loss results continuing to improve throughout the full 68-week trial period for most participants — suggesting that patience and consistency through the full timeline matters significantly for final outcomes.

Results beyond the scale

CagriReta weight loss results extend well beyond body weight alone. REDEFINE-1 demonstrated significant improvements in systolic blood pressure, waist circumference, lipid levels, and glycaemic control. The 88% normoglycemia finding among participants with prediabetes is particularly significant — it means the majority of people who started the trial on the path toward type 2 diabetes saw that risk effectively reversed.

The REIMAGINE clinical trial programme, studying CagriSema specifically in people with type 2 diabetes, found superior HbA1c reduction compared to semaglutide alone across all tested doses — alongside greater weight loss. This dual benefit positions CagriReta as a particularly compelling option for patients managing both weight and blood sugar simultaneously.

CagriReta vs Mounjaro and Wegovy

In the REDEFINE-4 head-to-head trial, Mounjaro produced slightly greater weight loss than CagriSema — 23.6% versus 20.2% over 84 weeks specifically. However, the two medications work through different mechanisms, and patients who do not tolerate or respond optimally to tirzepatide\’s GIP pathway may find CagriReta\’s amylin-based approach a better individual fit. See our complete CagriSema vs Mounjaro comparison for the full picture.

7 factors that affect your CagriReta weight loss results

• Adherence to the full dose escalation schedule — patients who follow the complete protocol consistently achieve results closer to the trial averages
• Protein intake — adequate protein (1.6 to 2.0g per kg body weight) preserves muscle mass and supports better overall body composition outcomes
• Regular exercise, particularly resistance training — protects lean mass and improves the proportion of weight lost that comes from fat
• Starting body weight and composition — patients with more weight to lose often see larger absolute losses, though percentage results vary individually
• Consistency of weekly injections — missed or delayed doses can disrupt the steady-state effect that drives continued weight loss
• Hydration and dietary quality — supports tolerability and allows patients to sustain treatment through the full timeline
• Individual metabolic and hormonal response — as with all GLP-1 and amylin therapies, some biological variation in response is expected and normal

Side effects to expect

REDEFINE-1 investigators specifically noted low, single-digit discontinuation rates due to adverse events — a positive tolerability signal for a medication combination producing such substantial CagriReta weight loss results. The most common side effects are gastrointestinal — nausea, vomiting, diarrhoea, and constipation — consistent with the broader GLP-1 and amylin medication class, and most pronounced during dose escalation phases. See our complete CagriReta side effects guide for the full breakdown.

Browse our full product range and read our verified customer reviews. For background on the medication itself, see our What is CagriReta guide.